Collegium Pharmaceutical, Inc. (COLL)
Collegium Pharmaceutical, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Stoughton, MA, US. The stock last traded at $22.53, down 0.49% on the session, giving a market capitalisation of $730.7M. On trailing twelve-month figures it carries a trailing P/E of 14.73, a net margin of 5.9%. Its beta of 0.72 implies it has historically moved less than the broad market.
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Collegium Pharmaceutical, Inc. is most often compared with the following Healthcare names: